News

• Intellia Therapeutics Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis (ATTR)
  10/19/2020 / 13:30 - GlobeNewswire
•  
• MATEON’S PHASE 2 GLOBAL STUDY FOR OT-101/ TGF-β INHIBITOR AGAINST COVID-19 CLEARED FOR PATIENT ENROLLMENT IN ARGENTINA.
  10/19/2020 / 13:00 - GlobeNewswire
•  
• We'll have more than one vaccine in 2021 - UK expert
  10/18/2020 / 11:08 - TeleTrader
•  
• US to provide Regeneron's drug for free - Trump
  10/16/2020 / 20:09 - TeleTrader
•  
• CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis
  10/16/2020 / 14:00 - GlobeNewswire
•  
• Dupixent® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase 3 trial
  10/13/2020 / 07:00 - GlobeNewswire
•  
• Trump: Regeneron drug most unbelievable thing
  10/09/2020 / 18:20 - TeleTrader
•  
• Fauci: Regeneron likely helped Trump
  10/08/2020 / 18:28 - TeleTrader
•  
• Regeneron, Eli Lilly going to get emergency approval - Trump
  10/08/2020 / 14:11 - TeleTrader
•  
• Trump says Americans to get COVID drugs for free
  10/07/2020 / 23:57 - TeleTrader
•  
• Dow jumps over 200 pts on open as Trump's health optimism rises
  10/05/2020 / 15:30 - TeleTrader
•  
• Regeneron jumps 5% premarket after Trump treatment
  10/05/2020 / 11:42 - TeleTrader
•  
• Regeneron's COVID treatment shows promise - study
  09/29/2020 / 22:21 - TeleTrader
•  
• Intellia Therapeutics Presents New Preclinical Data Showing Persistent In Vivo Editing and Durability of Effect Following CRISPR/Cas9-Based Treatment
  09/29/2020 / 14:20 - GlobeNewswire
•  
• Kiniksa Announces Rilonacept Analyst Day Now Tuesday, September 29th
  09/24/2020 / 22:12 - GlobeNewswire